Evidence map›Paper›PMID 25896924›Full record

ArticleBMC pharmacology & toxicology2015

Trypanocidal effect of the benzyl ester of N-propyl oxamate: a bi-potential prodrug for the treatment of experimental Chagas disease.

Carlos Wong-Baeza, Benjamín Nogueda-Torres, Manuel Serna, Sergio Meza-Toledo, Isabel Baeza, Carlos Wong

Open access · goldAbstract read
In one paragraph

Article in BMC pharmacology & toxicology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Effect of B-NIPOx in ExperimentalInternational journal of molecular sciences · 2022
    Article
  3. Review on Experimental Treatment Strategies AgainstJournal of experimental pharmacology · 2021
    Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Carlos Wong-BaezaBiochemistry Department, National School of Biological Sciences, National Polytechnic Institute, 11340, Mexico City, Mexico. charlywong@icloud.com.
Benjamín Nogueda-TorresParasitology Department, National School of Biological Sciences, National Polytechnic Institute, 11340, Mexico City, Mexico. bnogueda@yahoo.com.
Manuel SernaBiochemistry Department, National School of Biological Sciences, National Polytechnic Institute, 11340, Mexico City, Mexico. qbpjmserna@yahoo.com.
Sergio Meza-ToledoBiochemistry Department, National School of Biological Sciences, National Polytechnic Institute, 11340, Mexico City, Mexico. semeza@hotmail.com.
Isabel BaezaBiochemistry Department, National School of Biological Sciences, National Polytechnic Institute, 11340, Mexico City, Mexico. isabelbaeza@yahoo.com.
Carlos WongBiochemistry Department, National School of Biological Sciences, National Polytechnic Institute, 11340, Mexico City, Mexico. carloswongr@yahoo.com.
Instituto Politécnico Nacional · MXTecnológico Nacional de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChagas disease, which is caused by Trypanosoma cruzi, is a major health problem in Latin America, and there are currently no drugs for the effective treatment of this disease. The energy metabolism of T. cruzi is an attractive target for drug design, and we previously reported that inhibitors of α-hydroxy acid dehydrogenase (HADH)-isozyme II exhibit trypanocidal activity. N-Propyl oxamate (NPOx) is an inhibitor of HADH-isozyme II, and its non-polar ethyl ester (Et-NPOx) is cytotoxic to T. cruzi. A new derivative of NPOx has been developed in this study with higher trypanocidal activity, which could be used for the treatment of Chagas disease.

methodsThe benzyl ester of NPOx (B-NPOx) was synthesized and its activity evaluated towards epimastigotes and bloodstream trypomastigotes (in vitro), as well as mice infected with T. cruzi (in vivo). The activity of B-NPOx was also compared with those of Et-NPOx, benznidazole (Bz) and nifurtimox (Nx). NINOA, Miguz, Compostela, Nayarit and INC-5 T. cruzi strains were used in this study.

resultsPolar NPOx did not penetrate the parasites and exhibited no trypanocidal activity. In contrast, the hydrophobic ester B-NPOx exhibited trypanocidal activity in vitro and in vivo. B-NPOx exhibited higher trypanocidal activity than Et-NPOx, Bz and Nx towards all five of the T. cruzi strains. The increased activity of B-NPOx was attributed to its hydrolysis inside the parasites to give NPOx and benzyl alcohol, which is an antimicrobial compound with trypanocidal effects. B-NPOx was also effective against two strains of T. cruzi that are resistant to Bz and Nx.

conclusionB-NPOx exhibited higher in vitro (2- to 14.8-fold) and in vivo (2.2- to 4.5-fold) trypanocidal activity towards T. cruzi than Et-NPOx. B-NPOx also exhibited higher in vitro (2- to 24-fold) and in vivo (1.9- to 15-fold) trypanocidal activity than Bz and Nx. B-NPOx is more lipophilic than Et-NPOx, allowing for better penetration into T. cruzi parasites, where the enzymatic cleavage of B-NPOx would give NPOx and benzyl alcohol, which are potent trypanocidal agents. Taken together with its low toxicity, these results suggest that B-NPOx could be used as a potent prodrug for the treatment of Chagas disease.

Indexed as

Alcohol OxidoreductasesAnimalsCell LineCell SurvivalChagas DiseaseDisease Models, AnimalEstersIsoenzymesMaleMiceNifurtimoxNitroimidazolesOxamic AcidProdrugsTrypanocidal AgentsTrypanosoma cruziAlcohol OxidoreductasesbenzonidazoleD-2-hydroxyacid dehydrogenaseEstersIsoenzymesNifurtimoxNitroimidazolesN-propyl oxamate benzyl esterOxamic AcidProdrugsTrypanocidal Agents

Identifiers

PMID25896924
PMCPMC4409700
OpenAlexW2054183625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.